| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; data supports further development of b... |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; |
| 15 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
Q32 Bio Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (i) 6,027,399 shares of its common stock, $0.0001 par value per share, as set fo... |
| 13 Jul 2026 |
8-K: Other Events
Exhibit 99.1 SIGNAL-AA Part B 36-Week Topline Results July 2026 |
| 13 Jul 2026 |
8-K: Regulation FD Disclosure; Other Events
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata |
| 16 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
During the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Q32 Bio Inc. (the “Company”), the Company’s stockholders considered and voted on the three proposals set forth below, each of which is described in greater detail i... |
| 27 May 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of May 26, 2026 by and among Q32 Bio Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Inves... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- |
| 24 Apr 2026 |
8-K: Other Events
Securities Registered under Registration Statement on Form S-3 |
| 27 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
Q32 Bio Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: |
| 10 Mar 2026 |
8-K: Results of Operations and Financial Condition
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- |
| 17 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of February 17, 2026, between Q32 Bio Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its succes... |
| 19 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 01 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more
-- Asset sale further enables Company’s strategic focus on advancing bempikibart for alopecia areata -- |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- |
| 21 Oct 2025 |
8-K: Other Events
— SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients — |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H’26 -- |
| 25 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
— Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience — |
Loading...